Table 2: Selected clinical trials using lymphokine activated killer (LAK) cells.

ReferencePatientsImmunologic responseClinical response

[64]
(GBM: 7, AA: 2)
PR: 1
[91]
HGG
Cultured LAK cells lysed cultured glioma cells ( )Slight clinical (but not radiologic) improvement.
[92]
recurrent HGG
Median survival: 63 weeks
[93]
(GBM: 5, AA:4, Other 10)
CR: 1, PR: 2, median survival (GBM): 15 weeks
[94]
recurrent GBM
Median survival: 17.5 months (significantly longer than contemporary patients)
Others: [94, 143147]